Bone Sarcoma is an indication for drug development with over 220 pipeline drugs currently active. According to GlobalData, preregistered drugs for Bone Sarcoma have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Bone Sarcoma compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Bone Sarcoma

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bone Sarcoma overview

Bone sarcoma also known as bone cancer or primary bone cancer that starts in the bone. It is a rare type that can affect any part of the body but majorly legs. Osteosarcoma, Ewing sarcoma and chondrosarcoma are the types of bone cancer. Etiological factors are genetic, existing bone diseases especially pagets disease, previous exposure to radiation. Surgery, radiation therapy and chemotherapy are the management approaches.

For a complete picture of PTSR and LoA scores for drugs in Bone Sarcoma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.